protein kinase cAMP-dependent type II regulatory subunit alphaGenealiases: PKR2 · PRKAR2
Q-omics provides the consensus-scored PRKAR2A profile across patient tissues and cancer cell-line models. PRKAR2A expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, PRKAR2A is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, PRKAR2A protein abundance shows 26,763 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight COAD, KIRC, and LUAD as cancer lineages where PRKAR2A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRKAR2A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRKAR2A survival associations across molecular data types. PRKAR2A RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRKAR2A RNA expression–survival associations across cancer types. High PRKAR2A expression shows unfavorable associations in BLCA, KICH, LIHC and ACC, but favorable associations in COAD and KIRC. The COAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify COAD as the clearest survival context for PRKAR2A RNA expression.
This table summarizes PRKAR2A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PRKAR2A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRKAR2A shows lower tumor expression in KIRC, THCA, HNSC and KICH and higher tumor expression in LIHC and STAD. The KIRC box plot shows higher PRKAR2A RNA expression in normal versus tumor tissue (log2 FC = −0.617, t-test p < 0.001).
This table shows molecular features associated with PRKAR2A in patient tissues and cancer cell lines. In patient samples, PRKAR2A shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, PRKAR2A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and UPPER_AERODIGESTIVE_TRACT.
